Fortrea (NASDAQ:FTRE) and OpGen (NASDAQ:OPGN) Head-To-Head Review

Fortrea (NASDAQ:FTRE) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Fortrea and OpGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortrea	-10.99%	2.00%	0.80%
OpGen	-1,140.36%	N/A	-287.58%

Earnings & Valuation

This table compares Fortrea and OpGen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.70 billion	0.15	-$3.40 million	($3.69)	-1.20
OpGen	$2.67 million	18.46	-$32.67 million	N/A	N/A

Fortrea has higher revenue and earnings than OpGen.

Analyst Recommendations

This is a summary of current ratings for Fortrea and OpGen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	2	11	0	0	1.85
OpGen	0	0	0	0	0.00

Fortrea currently has a consensus target price of $15.00, suggesting a potential upside of 237.84%. Given Fortrea’s stronger consensus rating and higher possible upside, equities analysts clearly believe Fortrea is more favorable than OpGen.

Institutional and Insider Ownership

2.7% of OpGen shares are held by institutional investors. 0.1% of Fortrea shares are held by insiders. Comparatively, 43.8% of OpGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Fortrea has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.71, meaning that its share price is 271% less volatile than the S&P 500.

Summary

Fortrea beats OpGen on 8 of the 11 factors compared between the two stocks.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

About OpGen

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.